Administrative Restructuring Versus Product Safety: The Case for Subsequent Importer Scheme (SIS) in Importer Constitutional Changes

As the Indian medical device ecosystem reaches a state of rigorous maturity, a significant friction point has emerged between corporate governance and regulatory oversight. Currently, when an established importer, an entity with an unblemished history of compliance, undergoes a routine constitutional change (such as a transition from a private limited to a limited company), the regulator often mandates a "fresh license" application. This administrative requirement effectively ignores the entity’s entire history of post-market surveillance (PMS) and safety compliance, treating a seasoned market participant as a brand-new entrant. This article examines the "importer paradox" and argues that the logic of the Central Drugs Standard Control Organisation's (CDSCO) "Subsequent Importer Scheme" (SIS) provides a compelling blueprint for reform. We propose a shift in regulatory philosophy: prioritizing the "Safety Anchor" of the medical device, which is tethered to its technical file and manufacturing site, over the "Legal Wrapper" of the corporate entity. By adopting a streamlined three-step transition involving a formal declaration of continuity, integration through the SIS portal, and a targeted administrative audit, the regulator can eliminate redundant filings. This approach would not only reduce the administrative burden on both the reviewer and the manufacturer but also ensure a more transparent and secure supply chain for Indian patients. Ultimately, regulatory science must recognize that corporate evolution should not be a trigger for technical re-evaluation when the underlying product safety remains unchanged.